相关实验视频

Updated: May 5, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

在多发性骨髓瘤中达拉图穆马布,莱纳利多米德和甲的相对剂量强度

Kazuhito Suzuki¹, Tadahiro Gunji¹, Masaharu Kawashima¹

¹Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Minato City 105-8461, Japan.

|February 13, 2025

概括

达拉图穆马布的高相对剂量强度 (RDI) 和德克萨梅他的低RDI与多发性骨髓瘤患者治疗DRd治疗的改善结果相关. 这表明RDI是治疗成功的关键因素.

科学领域:

血液学血液学血液学
在瘤学瘤学.
临床研究临床研究

背景情况:

达拉图穆马布 (DARA),莱纳利多米德 (LEN) 和德克萨米他 (DRd) 是多发性骨髓瘤 (MM) 的标准治疗方法.
在接受DRd治疗的患者中,相对剂量强度 (RDI) 对临床结果的影响尚不清楚.

研究的目的:

调查DRd组件的RDI与MM患者的临床结果之间的关联.
确定RDI是否影响到下一次治疗的时间 (TTNT) 和整体存活率 (OS).

主要方法:

对111名新诊断,复发或耐药MM患者的回顾性分析,这些患者接受了DRd.治疗.
计算DARA,LEN和DEX的RDI,以及与TTNT,OS和严重感染的相关性.

主要成果:

高RDI的DARA (>90%) 与显著更长的TTNT (77.3%对比51.6%,p <0.001) 有关.
低DEX的RDI (<15%) 与较长的生存期有关 (87.7%与61.0%,p = 0.027).
高DARA RDI和低DEX RDI与减少严重感染和改善生存结果相关.

结论:

DARA的高RDI和DEX的低RDI预测了DRd治疗MM患者的良好临床结果.
在DRd疗法中的单个药物的RDI可能在治疗疗效和患者存活率方面发挥关键作用.

关键词:

在达拉图姆巴姆巴布.德克萨米他是一种感染的感染感染.莱纳利多胺的使用方法多发性骨髓瘤是多发性骨髓瘤的一种疾病.相对剂量强度的相对剂量强度.幸存率幸存率生存率

更多相关视频

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

相关概念视频

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...